



**Johnson & Johnson and Subsidiaries  
Reconciliation of Non-GAAP Measures**

<i>(Dollars in Millions Except Per Share Data)</i>	Second Quarter		% Incr. / (Decr.)	June YTD		% Incr. / (Decr.)
	2007	2006		2007	2006	
<b>Net Earnings - as reported</b>	\$ 3,081	2,820	9.3%	\$ 5,654	6,125	-7.7%
Guidant acquisition agreement termination fee	-	-		-	(368)	
In-process research & development (IPR&D)	-	87		807	116	
<b>Net Earnings - as adjusted</b>	<b>\$ 3,081</b>	<b>2,907</b>	<b>6.0%</b>	<b>\$ 6,461</b>	<b>5,873</b>	<b>10.0%</b>
<b>Diluted Net earnings per share - as reported</b>	\$ 1.05	0.95	10.5%	\$ 1.93	2.05	-5.9%
Guidant acquisition agreement termination fee	-	-		-	(0.12)	
In-process research & development (IPR&D)	-	0.03		0.28	0.04	
<b>Diluted Net earnings per share - as adjusted</b>	<b>\$ 1.05</b>	<b>0.98</b>	<b>7.1%</b>	<b>\$ 2.21</b>	<b>1.97</b>	<b>12.2%</b>

The Company believes investors gain additional perspective of underlying business trends and results by providing a measure of net earnings and diluted net earnings per share that excludes IPR&D and the Guidant acquisition agreement termination fee in order to evaluate ongoing business operations.

**Johnson & Johnson**  
**2007 Q2 As Reported and Pro-Forma Net Trade Sales**  
**Reported and Operational Growth Rates**

	SECOND QUARTER				SIX MONTHS			
	Reported Growth		Pro-Forma Growth <sup>1</sup>		Reported Growth		Pro-Forma Growth <sup>1</sup>	
	Total%	Oper.%	Total%	Oper.%	Total%	Oper.%	Total%	Oper.%
Skin Care	16%	12	10%	7	16%	13	10%	7
Baby & Kids Care	16	11	14	9	13	9	11	7
Oral Care	240	238	1	(2)	261	259	7	4
OTC / Nutritionals	91	88	5	3	92	89	8	6
Women's Health	11	7	6	2	9	5	3	0
<b>Consumer Segment Worldwide</b>	<b>49%</b>	<b>45</b>	<b>8%</b>	<b>5</b>	<b>49%</b>	<b>45</b>	<b>9%</b>	<b>6</b>
<b>Worldwide</b>	<b>13%</b>	<b>11</b>	<b>6%</b>	<b>4</b>	<b>15%</b>	<b>12</b>	<b>7%</b>	<b>5</b>

1) 2006 baseline includes Pfizer Consumer Health (PCH) sales and excludes PCH acquisition related divestitures